ALLO
Allogene Therapeutics Inc
NASDAQ: ALLO · HEALTHCARE · BIOTECHNOLOGY
$2.13
+0.95% today
Updated 2026-04-30
Market cap
$725.79M
P/E ratio
—
P/S ratio
7,784.36x
EPS (TTM)
$-0.87
Dividend yield
—
52W range
$1 – $4
Volume
10.3M
Allogene Therapeutics Inc (ALLO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-53.40%
ROA
-26.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $0.00 | $-2000.00 | — | — | — |
| 2018 | $0.00 | $-211.50M | — | — | — |
| 2019 | $0.00 | $-184.59M | — | — | — |
| 2020 | $38.34M | $-233.47M | -30.10% | -673.47% | -608.87% |
| 2021 | $38.49M | $-244.84M | 100.00% | -664.58% | -636.12% |
| 2022 | $243000.00 | $-329.81M | 100.00% | -138,044.86% | -135,726.34% |
| 2023 | $95000.00 | $-327.26M | 100.00% | -344,986.32% | -344,489.47% |
| 2024 | $22000.00 | $-257.59M | 100.00% | -1,241,813.64% | -1,170,863.64% |
| 2025 | $0.00 | $-190.89M | — | — | — |